Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-α-difluoromethyl-ornithine in plasma

Abstract

The aim of this study was to synthesize a series of mono-, di- and trisubstituted derivatives of the human African trypanosomiasis drug eflornithine (α-difluoro-methylornithine, DMFO, CAS 70052-12-9) to determine their partition coefficients, and to assess whether they deliver the parent drug in the plasma. If increased plasma concentrations of eflornithine could be achieved in this way, an oral dosage form would be possible. The derivatives, nine in total, were successfully synthesized by multi-step derivatisation of eflornithine on either its α-carboxylic or/and α-amino or/and 5-amino groups by either esterification or/and amidation or/and carbamylation, and their structures confirmed by NMR and MS spectroscopy. The majority of derivatives were more lipophilic than eflornithine with log D values in phosphate buffer solution (pH 7.4) ranging from −1.34 to 1.59 (vs. −0.98 for eflornithine). The in vivo absorption after oral administration to Sprague-Dawley rats showed that no derivative delivered eflornithine in the plasma, indicating that the derivatives were either not absorbed from the gastrointestinal tract or not metabolized to the parent drug. Two of the monosubstituted activities were toxic for T. brucei blood stream forms.

Key words

α-Difluoromethylornithine - Eflornithine derivatives - Human African trypanosomiasis (HAT) - Sleeping sickness - Trypanosoma brucei gambiense

• References

• 1 WHO. Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee. Geneva: World Health Organization 1998
• 2 Delespaux V, de Koning H.. Drugs and drug resistance in African trypanosomiasis. Drug Resist Updates. 2007; 10: 30-50
• 3 Stanghellini A, Josenando T.. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health. 2001; 6: 330-4
• 4 Bouteille B, Oukem O, Bisser S, Dumas M.. Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol. 2003; 17: 171-81
• 5 Fairlamb A.. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 2003; 9: 488-94
• 6 Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U.. Melarsoprol versus eflornithine for treating late-stage gambian trypanosomiasis in the republic of the Congo. Bull World Health Organ. 2006; 84: 783-91
• 7 Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud M, Checchi F.. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Trans R Soc Trop Med Hyg. 2009; 103: 280-90
• 8 Matovu E, Seebeck T, Enyaru JCK, Kaminsky R.. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 2001; 3: 763-70
• 9 Denise H, Barrett MP.. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol. 2001; 61: 1-5
• 10 McCann PP, Pegg AE.. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992; 54: 195-215
• 11 Chappuis F.. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Clin Infect Dis. 2007; 45: 1443-5
• 12 Iten M, Mett H, Evans A, Enyaru J, Brun R, Kaminsky R.. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-difluoromethylornithine. Antimicrob Agents Chemother. 1997; 41: 1922-5
• 13 Burri C, Brun R.. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003; 90: S49-52
• 14 Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, Kuzoe F. The pharmacokinetics of eflornithine (α-difluoromethylomithine) in patients with late-stage T[[dot]]b. gambiense sleeping sickness. Eur J Clin Pharmacol. 2004; 60: 269-78
• 15 March’s Advanced Organic Chemistry: reactions, mechanisms, and structure. New York: Wiley & Sons 1992: 293-500
• 16 Montalbetti CAGN, Falque V.. Amide bond formation and peptide coupling. Tetrahedron. 2005; 61: 10827-52
• 17 Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P et al Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J. 2003; 375: 465-70
• 18 N’Da DD, Breytenbach JC.. Synthesis of methoxypoly(ethy-lene glycol) carbonate prodrugs of zidovudine and penetration through human skin in vitro. J Pharm Pharmacol. 2009; 61: 721-31
• 19 Jansson R, Malm M, Roth C, Ashton M.. Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. Antimicrob Agents Chemother. 2008; 52: 2842-8
• 20 Jansson-Löfmark R, Römsing S, Albers E, Ashton M.. Determination of eflornithine enantiomers in plasma by precolumn derivatisation with o-phthalaldehyde-N-acetyl-1-cy-steine and liquid chromatography with UV detection. Biomed Chromatogr. 2010; 24: 794-7
• 21 Vodnala SK, Ferella M, Lundén-Miguel H, Betha E, van Reet N, Amin DN et al Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl Trop Dis. 2009; 3 ((8)) e495
• 22 Chollet C, Baliani A, Barrett MP, Gilbert IH.. Targeted delivery of compounds to trypanosoma brucei using the mela-mine motif. Bioorg Med Chem. 2009; 17: 2512-23
• 23 Shargel L, Yu ABC. Physiologic factors related to drug absorption. In: Applied Biopharmaceutics and Pharmacokinetics. Shargel L, Yu ABC, editors. Norwalk (CT, USA): Appleton & Lange; 1999: 99-121
• 24 Caron G, Reymond F, Carrupt P, Girault HH, Testa B.. Combined molecular lipophilicity descriptors and their role in understanding intramolecular effects. Pharm Sci Tech Today. 1999; 2: 327-35
• 25 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3-26
• 26 Ghose AK, Viswanadhan VN, Wendoloski JJ.. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999; 1: 55-68
• 27 Silverman RB. The organic chemistry of drug design and drug action. Amsterdam: Elsevier Academic Press; 2004
• 28 Helena KJ, N’Da DD, Johansson CC, Breytenbach JC, Ashton M.. Effects of oral administration of synthesized δ-amides of eflornithine in the rat. Arzneimittelforschung. 2010; 60 ((11)) 682-8